Targeted pill shows promise for rare lung cancer mutation in chinese patients

NCT ID NCT04677595

Completed Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested an oral targeted drug called capmatinib in 36 Chinese adults with advanced non-small cell lung cancer that has a specific MET gene mutation (exon 14 skipping). The drug aims to block faulty signals that help cancer grow. Researchers measured how many patients' tumors shrank or disappeared.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: capmatinib (oral targeted therapy)
What this could lead to: If successful, this could provide a new targeted treatment option for Chinese patients with this specific type of lung cancer.
What could go wrong: This is a small Phase 2 study with only 36 participants, so results may not apply to all patients. The drug may not work as well in a broader population or may have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER (NSCLC)

Contacts and locations

Locations

Novartis Investigative Site

Xiamen, Fujian, 361001, China
Novartis Investigative Site

Foshan, Guangdong, 528000, China
Novartis Investigative Site

Guangzhou, Guangdong, 510080, China
Novartis Investigative Site

Guangzhou, Guangdong, 510515, China
Novartis Investigative Site

Guangzhou, Guangdong, 524000, China
Novartis Investigative Site

Harbin, Heilongjiang, 150000, China
Novartis Investigative Site

Zhengzhou, Henan, 450003, China
Novartis Investigative Site

Wuhan, Hubei, 430024, China
Novartis Investigative Site

Shenyang, Liaoning, 110001, China
Novartis Investigative Site

Jinan, Shandong, 250117, China
Novartis Investigative Site

Shanghai, Shanghai Municipality, 200030, China
Novartis Investigative Site

Chengdu, Sichuan, 610041, China
Novartis Investigative Site

Kunming, Yunnan, 650106, China
Novartis Investigative Site

Hangzhou, Zhejiang, 310022, China
Novartis Investigative Site

Beijing, 100142, China
Novartis Investigative Site

Shanghai, 200030, China
Novartis Investigative Site

Tianjin, 300052, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.